Global Lysosomal Storage Diseases Market 2014-2018

Global Lysosomal Storage Diseases Market 2014-2018

Category : Healthcare
Published On : July  2014
Pages : 64

------------ Or -------------

About Lysosomal Storage Diseases
The term lysosomal storage diseases refers to a group of rare inherited disorders caused by the deficiency of lysosomal enzymes, activator proteins, proteins required for normal post-translational modification of lysosomal enzymes or proteins required for intracellular transport between lysosome and other cellular compartments. These deficiencies result in deficient enzymatic activity which, in turn, leads to accumulation of partially digested or undigested macromolecules inside the cell. The clinical manifestations of lysosomal storage diseases depend on the type of substrate stored, cell types affected by this storage, and resulting organ involvement. Due to the high variability of these components, the clinical manifestations of even a single disease vary from person to person. These symptoms also vary between members of the same family with identical mutations. The age of onset also varies for lysosomal storage diseases depending on the rate of substrate accumulation. Lysosomal storage diseases are classified on the basis of the substrate being accumulated or on the type of molecular defect associated with the disease. Neuronal ceroid-lipofuscinoses vary from classical lysosomal storage diseases where the component that gets accumulated is mitochondrial ATP synthase subunit C or sphingolipid activator proteins A and D.

TechNavio's analysts forecast the Global Lysosomal Storage Diseases market will grow at a CAGR of 10.01 percent over the period 2013-2018.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Lysosomal Storage Diseases market for the period 2014-2018. To calculate the market size, the report considers revenue from the sales of various drugs available in the market for the management of different types of lysosomal storage diseases, which include:
• Gaucher disease
• Fabry disease
• Mucopolysaccharidosis
• Pompe disease
• Cystinosis
TechNavio's report, the Global Lysosomal Storage Diseases Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Lysosomal Storage Diseases market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas 
• EMEA        
Key Vendors
• Actelion Pharmaceuticals Ltd.
• BioMarin Pharmaceutical Inc.
• Genzyme Corp.
• Shire plc 
Other Prominent Vendors
 • Mylan
• Pfizer
• Protalix
• Raptor
• Recordati
• Sigma-Tau
Key Market Driver
• Special Provisions for Orphan Drugs
• For a full, detailed list, view our report.
Key Market Challenge
• Increase in Generic Erosion
• For a full, detailed list, view our report.
Key Market Trend
• Fierce Market Competition
• Increasing Use of Statins.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

Product Portfolio

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Disease Overview

07. Market Landscape

07.1 Market Overview

07.2 Market Size and Forecast

07.3 First Approved Drugs for Treatment of Lysosomal Storage Diseases

07.4 Five Forces Analysis

08. Market Segmentation by Drug Class

08.1.1 ERTs

08.1.2 SRT

08.1.3 Cystine-Depletors

09. Geographical Segmentation

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

17.1 Competitive Scenario

17.1.1 Key News

17.1.2 Mergers and Acquisitions

17.2 Market Share Analysis 2013

17.2.1 Genzyme

17.2.2 Shire

17.2.3 BioMarin

17.2.4 Actelion

18. Others

18.1 Other Prominent Vendors

19. Key Vendor Analysis

19.1 Actelion

19.1.1 Business Overview

19.1.2 Key Information

19.1.3 SWOT Analysis

19.2 BioMarin

19.2.1 Business Overview

19.2.2 Key Information

19.2.3 SWOT Analysis

19.3 Genzyme

19.3.1 Business Overview

19.3.2 Key Information

19.3.3 SWOT Analysis

19.5 Shire

19.5.1 Business Overview

19.5.2 Key Information

19.5.3 SWOT Analysis

20. Other Reports in this Series

List of Exhibits

Exhibit 1: Market Research Methodology

Exhibit 2: Classification of Lysosomal Storage Diseases

Exhibit 3: Global Lysosomal Storage Diseases Market 2013-2018 (US$ billion)

Exhibit 4: Global Lysosomal Storage Diseases Market Segmentation by Drug Class

Exhibit 5: Global Lysosomal Storage Diseases Market Segmentation by Drug Class 2013

Exhibit 6: Global Lysosomal Storage Diseases Market by Geographical Segmentation 2013

Exhibit 7: Market Revenue for Major Drugs 2013

Exhibit 8: Percentage Revenue Share of LSD Drugs of Genzyme 2013

Exhibit 9: Geography-wise Revenue of Genzyme Corp.’s LSD Products in 2013 (US$ million)

Exhibit 10: Geography-wise Revenue of Genzyme Corp’s LSD Products in 2013

Exhibit 11: Geography-wise Revenue of Naglazyme in 2013 (US$ million)

Enquiry Before Buy